Hemodynamics, fluids & transfusion
Strategies for discontinuing vasopressin and norepinephrine during the recovery phase of shock: a single-center retrospective study
Authors' conclusion
In patients recovering from shock who received both arginine vasopressin and norepinephrine, discontinuing arginine vasopressin first was not associated with a higher risk of hypotension.
Study context
- Population
- ICU patients with shock who received both arginine vasopressin and norepinephrine, August 2017 to March 2024analysed
- Participants
- 524 patients
- Exposure
- AVP-first vs NE-first
- AVP-firstn = 293
- NE-firstn = 231reference
- Outcome
- Incidence of hypotension (MAP < 60 mmHg requiring a ≥ 25% increase in the remaining vasopressor, reinstitution of the stopped agent, or a bolus of ≥ 500 mL crystalloid or 25 g albumin)
- Follow-up
- Within 24 h of vasopressor cessation
Methodological detailssingle-centre, propensity-score overlap weighting
- Single-centre
- Propensity-score overlap weighting
Main finding
As reported in the abstract
Hypotension within 24 h of vasopressor cessation · 24 h
Incidence of hypotension after overlap weighting, not significantly different
19% vs 21%
Observational data: associations, not effects.
Further findings
- Hypotension (unadjusted) — NE-first
- 26%
Hypotension, septic shock subgroup (n = 267, weighted)
- No significant difference between groups
Original publication
Strategies for discontinuing vasopressin and norepinephrine during the recovery phase of shock: a single-center retrospective study. J Intensive Care. Published 30 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →